Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 189 of 189 entries
View as:

A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT02236013 Org: User:
Start: 01/07/15 End: 07/26/21 Due: 07/26/22

Study to Investigate the Absorption, Metabolism and Excretion of [14C] ASP2215 in Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02456883 Org: User:
Start: 03/04/16 End: 06/19/17 Due: 06/19/18

A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06862219 Org: User:
Start: 03/31/25 End: 12/31/27 Due: 12/31/28

Drug Interaction Study of the Effect of Ketoconazole at Steady State on the Pharmacokinetics of a Single Dose of Isavuconazole in Healthy Adult Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01657838 Org: User:
Start: 05/31/12 End: 05/31/12 Due: 05/31/13

Bioavailability of ASKP1240 in Healthy Subjects After Intravenous and Subcutaneous Administration of ASKP1240

Phase: N/A Priority: Normal
NCT ID: NCT01582399 Org: User:
Start: 02/29/12 End: 09/30/12 Due: 09/30/13

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MA-0211 in Healthy Adult Subjects Including a Food Effect Cohort

Phase: N/A Priority: Normal
NCT ID: NCT03682484 Org: User:
Start: 06/29/17 End: 03/26/18 Due: 03/26/19

Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen

Phase: N/A Priority: Normal
NCT ID: NCT04837196 Org: User:
Start: 12/06/21 End: 06/21/24 Due: 06/21/25

A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06681870 Org: User:
Start: 12/31/24 End: 03/31/29 Due: 03/31/30

A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Metformin

Phase: N/A Priority: Normal
NCT ID: NCT01884558 Org: User:
Start: 02/28/13 End: 02/28/13 Due: 02/28/14

A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015K

Phase: N/A Priority: Normal
NCT ID: NCT01686217 Org: User:
Start: 06/30/12 End: 07/31/12 Due: 07/31/13

A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT01565655 Org: User:
Start: 06/19/12 End: 12/02/13 Due: 12/02/14

A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

Phase: N/A Priority: Normal
NCT ID: NCT02757768 Org: User:
Start: 06/13/16 End: 09/11/18 Due: 09/11/19

A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Phase: N/A Priority: Normal
NCT ID: NCT02495233 Org: User:
Start: 09/08/15 End: 09/28/16 Due: 09/28/17

A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)

Phase: N/A Priority: Normal
NCT ID: NCT04641975 Org: User:
Start: 03/15/21 End: 07/24/23 Due: 07/24/24